Transcatheter arterial chemoembolization after stopping sorafenib therapy for advanced hepatocellular carcinoma

Yao-Kuang Huang¹, Chieh-Ling Yen¹, Sz-Iuan Shiu¹, Shou-Wu Lee¹,², Pi-Yi Chang³, Hong-Zen Yeh¹, Teng-Yu Lee¹,²*¹

¹ Division of Gastroenterology & Hepatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan, ² Department of Medicine, Chung Shan Medical University, Taichung, Taiwan, ³ Department of Radiology, Taichung Veterans General Hospital, Taichung, Taiwan

* tylee@vghtc.gov.tw

Abstract

Targeted therapy is currently the standard treatment for advanced hepatocellular carcinoma (HCC), but an effective treatment after the discontinuation of sorafenib therapy remains uncertain. We aim to investigate the survival benefits of transcatheter arterial chemoembolization (TACE) after stopping sorafenib therapy. We retrospectively analyzed all patients with advanced HCC, who had received palliative TACE after terminating sorafenib therapy, from January 2008 to June 2016. Patients who were in the terminal stage (Child-Pugh class C or performance status 3–4), who received a liver transplantation, or who had received any HCC treatment other than TACE, were excluded. Finally, 28 patients were recruited as the TACE group, and were randomly matched 1:1 by age, gender, Child-Pugh class, extrahepatic metastasis, and portal vein thrombosis with 28 controls who only received supportive care. For avoiding any immortal time bias, the index date of outcome follow-up was also matched. Cumulative incidences of, and hazard ratios (HRs) for, patient mortality were analyzed. The baseline demographic data between the TACE group and the control group were similar, but the 1-year overall survival rate in the TACE group was significantly higher than that of the control group (41.2%, 95% confidence interval [CI]: 19.4–63.0% vs. 24.5%, 95% CI: 6.3–42.7%; \( p < 0.01 \)). In multivariate analysis, after adjusting for alpha-fetoprotein > 400ng/mL, Child-Pugh class B, and tumor extension > 50% of liver volume, TACE was independently associated with a decreased mortality risk (HR 0.19, 95% CI: 0.08–0.42). In addition, tumor extension > 50% of the liver was another independent prognostic factor associated with an increased mortality risk (HR 2.99, 95% CI: 1.31–6.82). Multivariate stratified analyses verified the association of TACE with a decreased mortality rate in each patient subgroup (all HR < 1.0). By controlling intrahepatic tumor growth, TACE may be a treatment option for use in improving patient survival in advanced HCC, after the termination of sorafenib therapy.
Introduction

Hepatocellular carcinoma (HCC) is currently the second leading cause of cancer mortality worldwide [1]. Unfortunately, approximately one third of the patients belong to the advanced stage of HCC, with an average survival period of only 6–12 months [2]. Sorafenib is currently the standard treatment for advanced stage HCC [3,4]. However, the response rate of sorafenib therapy has been reported in previous literature to be less than 5%, while the median patient survival time was prolonged for only about 3 months [3]. Moreover, as many as 30–40% of patients could not tolerate the side effects of sorafenib therapy, so it had to be discontinued early [5,6]. Thus, the majority of patients with advanced HCC who were treated with sorafenib, will eventually stopped sorafenib therapy due to either disease progression or side effect intolerance. Unfortunately, after stopping sorafenib therapy, the one-year patient survival rate was only around 30–40% [7,8]. Therefore, finding an effective treatment to improve patient survival after stopping sorafenib therapy for advanced HCC is mandatory.

Although clinical trials for second-line systemic treatment after stopping sorafenib therapy have been conducted, the overwhelming majority of studies’ results were disappointing [9–12]. Currently, according to the international practice guidelines for the management of HCC, an available rescue treatment after cessation of sorafenib therapy remains unclear [4,13]. Furthermore, although regorafenib has recently been approved as a second-line treatment for HCC patients who have previously received sorafenib therapy [14], a wider use of the drug in the real world is still pending. It remains urgent to establish an effective, approachable and affordable alternative treatment for patients upon their termination from sorafenib therapy.

Transcatheter arterial chemoembolization (TACE) is an effective local-regional treatment for HCC, where TACE can improve patient survival rates and has been recommended as the standard treatment for intermediate-stage HCC [15,16]. Moreover, TACE may also improve patient survival in select patients with advanced HCC [17,18]. Although extrahepatic metastases may exist in advanced-stage HCC, patients may still die of intrahepatic tumor progression [19]. In this way, TACE may improve survival through its control of intrahepatic tumors [19,20]. However, the evidence supporting the use of TACE for advanced HCC after stopping sorafenib therapy remains lacking. In this study, by comparing patients receiving palliative TACE with those who are not, we aimed to assess the survival benefits of TACE after patients had stopped sorafenib therapy.

Materials and methods

Study design

This retrospective cohort study was conducted at a tertiary referral center in central Taiwan. All patients who were diagnosed as having advanced HCC and had received sorafenib therapy were screened from January 2008 to June 2016. HCC was diagnosed through either pathological confirmation or typical dynamic image presentations of HCC according to the current practice guidelines [21]. The image studies were independently reviewed by two radiologists. This study was approved by the Ethics Committee of Taichung Veterans General Hospital.

Study subjects

The flow algorithm of patient selection is shown in Fig 1. We located all 282 adult patients who were in advanced-stage HCC and had received sorafenib therapy from January 2008 to June 2016. At the time of stopping sorafenib therapy, any patients whose liver function belonged in Child-Pugh class C, and whose performance status belonged in Eastern Cooperative Oncology Group score 3–4 were excluded. In addition, the patients who had received any HCC treatment before were also excluded. The remaining 171 patients were divided into two groups: the TACE group (n=100) and the no-TACE group (n=71). The TACE group included patients who had undergone at least one TACE procedure during the follow-up period after stopping sorafenib therapy. The no-TACE group included patients who had not undergone TACE during the follow-up period.

Competing interests: The authors have declared that no competing interests exist.
treatment other than TACE after stopping sorafenib therapy, including radiotherapy, systemic chemotherapy or other therapies in clinical trials, were also excluded. Thus, patients were divided into two groups according to whether they had received TACE (the TACE cohort) or had not (the control cohort) after stopping sorafenib therapy. Furthermore, patients in the TACE cohort were randomly matched 1:1 with patients in the control cohort by age, gender, Child-Pugh class, extrahepatic metastasis, portal vein thrombosis, and tumor size. Eventually, 28 patients were recruited from both the TACE group and the control group for final analysis in this study.

Patient selection for TACE treatment

According to the consensus guideline for HCC management of the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan [22] although sorafenib is the standard systemic therapy for patients with advanced HCC, TACE may also be considered as a locoregional treatment in patients not experiencing severe liver decompensation (Child-Pugh C). However, the survival benefits of TACE treatment after stopping sorafenib therapy remain uncertain, so only a proportion of patients in Child-Pugh A or B would be recommended for TACE.

TACE procedure

Only conventional TACE is reimbursed by the National Health Insurance in Taiwan. Basically, the feeding arteries of HCCs were selectively catheterized for the purpose of preserving liver parenchyma, before transarterial chemotherapy was performed using a mixture of lipiodol and a chemotherapeutic agent. The feeding arteries were subsequently embolized with gel foam until complete flow stagnation was achieved.

Main outcome measurement

Cumulative incidences of patient mortality were calculated, with the major outcome in this study being the overall survival rate over one year. The index date of outcome follow-up was
the date of the first TACE in the TACE group. For the purpose of eliminating any immortal 
time bias, the follow-up index date of the matched control was given by matching the time 
period between the sorafenib stopping date and the first TACE date [23,24]. Patients were fol-
lowed up until either mortality, or the end of the one-year follow-up.

Prognostic factor assessment
Detailed data regarding potential prognostic factors were individually retrieved from the medi-
cal records of study subjects, including Child-Pugh score, Alpha-fetoprotein (AFP) levels, per-
formance status and tumor image characteristics on the index date of outcome follow-up. In 
addition, data on the dosage and duration of sorafenib therapy, the reasons for sorafenib with-
drawal, and the history of local-regional HCC treatment prior to sorafenib therapy were also 
collected.

Statistical analysis
Continuous data was presented as median values (25%-75% interquartile ranges), and tested 
with Wilcoxon signed rank test. Discrete data was shown as numbers (percentages), and tested 
with the McNemar test. Cumulative incidences of overall mortality after the follow-up index 
date were calculated, and the calculated rates were expressed as the estimated number, along 
with the 95% confidence interval (CI). One-year overall survival rates were compared using 
the Kaplan-Meier’s method. After adjusting for potential confounding factors, multivariate 
regression analyses were conducted to determine the independent prognostic factors for over-
all mortality, while hazard ratios (HRs) were determined by Cox proportional hazard models. 
Multivariate stratified analysis for the effect of TACE was also performed in patient subgroups. 
All data was analyzed using SPSS 22.0 (SPSS, Chicago, IL).

Results
Baseline demographic characteristics
Prior to matching the baseline characteristics of the two study cohorts, the liver function pro-
files were shown to be significantly better in the TACE cohort than those in the control cohort 
(S1 Table). However, as shown in Table 1, the baseline demographic characteristics of the two 
groups were similar after patient matching. The median age of patients was 61 years old, and 
around 80% of patients were males. Nearly 90% of patients were infected with hepatitis virus B 
or C, and more than 40% of patients suffered from liver decompensation (Child-Pugh class B). 
In addition, the tumor status was quite severe in both groups. Most (> 50%) patients had 
extrahepatic metastases, while portal vein thrombosis could be found in more than 70% of 
patients. An AFP elevation > 400ng/ml was also common (~50%), and approximately 60% of 
patients suffered from a tumor morphology extension > 50% of the liver. The median point of 
the Cancer of the Liver Italian Program (CLIP) score was found to be as high as 3.

Before initiating sorafenib therapy, the majority of patients were not treatment-naïve (patient conditions prior to the initiation of sorafenib therapy are compared between the two study groups in S2 Table, and the patient characteristics remained similar between the two study groups). During sorafenib therapy, the median daily dose of sorafenib initiation was 400mg in both groups. Although the median maximum daily dose of sorafenib therapy was 800mg and 400mg daily in the control group and the TACE group respectively, the difference was not statistically significant. The median duration of sorafenib therapy was approximately 11 weeks in both groups, and more than 85% of patients stopped sorafenib therapy due to dis-
ease progression. In the TACE group, the median number of TACE course that patients
received was 2 times, and the median duration from stopping sorafenib therapy to the first TACE was 34 days.

**Overall survival**

Before matching the follow-up index date of the two groups in order to eliminate any immortal time bias, the median duration of patient survival in the TACE group was shown to be significantly longer than that of the control group (11.7 months, 95% CI: 6.0–17.4 months vs. 3.8 months).

| Variables                      | Control Group (n = 28) | TACE Group (n = 28) | p    |
|-------------------------------|------------------------|--------------------|------|
| Age, year                     | 60.5 (50.8–70.8)       | 60.9 (50.0–70.9)   | 0.25 |
| Gender, n (%)                 |                        |                    | 0.69 |
| Male                          | 22 (78.6%)             | 24 (85.7%)         |      |
| Female                        | 6 (21.4%)              | 4 (14.3%)          |      |
| Etiology of disease, n (%)    |                        |                    | 0.99 |
| Viral                         | 25 (89.3%)             | 24 (85.7%)         |      |
| Non-viral                     | 3 (10.7%)              | 4 (14.3%)          |      |
| Child-Pugh class, n (%)       |                        |                    | 0.99 |
| A                             | 15 (53.6%)             | 16 (57.1%)         |      |
| B                             | 13 (46.4%)             | 12 (42.9%)         |      |
| Extrahepatic metastases, n (%)|                        |                    | 0.77 |
| No                            | 13 (46.4%)             | 11 (39.3%)         |      |
| Yes                           | 15 (53.6%)             | 17 (60.7%)         |      |
| Portal vein thrombosis, n (%) |                        |                    | 0.75 |
| No                            | 8 (28.6%)              | 6 (21.4%)          |      |
| Yes                           | 20 (71.4%)             | 22 (78.6%)         |      |
| AFP, ng/mL                    |                        |                    | 0.79 |
| > 400                         | 14 (50.0%)             | 16 (57.1%)         |      |
| ≤ 400                         | 14 (50.0%)             | 12 (42.9%)         |      |
| Tumor morphology, n (%)       |                        |                    | 0.77 |
| Extension ≤ 50%               | 12 (42.9%)             | 10 (35.7%)         |      |
| Extension > 50%               | 16 (57.1%)             | 18 (64.3%)         |      |
| CLIP score, point             | 3 (2–4)                | 3 (2–4)            | 1.00 |
| Tx-naive before sorafenib therapy |                    |                    | 0.38 |
| Yes                           | 4 (14.3%)              | 1 (3.6%)           |      |
| No                            | 24 (85.7%)             | 27 (96.4%)         |      |
| Sorafenib therapy             |                        |                    |      |
| Initial daily dose, mg        | 400 (400–800)          | 400 (400–800)      | 0.45 |
| Maximum daily dose, mg        | 800 (400–800)          | 400 (400–800)      | 0.45 |
| Therapy duration, day         | 80 (42–243)            | 77 (42–169)        | 0.66 |
| Reasons to stop sorafenib, n (%)|                        |                    | 0.38 |
| Disease progression           | 24 (85.7%)             | 27 (96.4%)         |      |
| Intolerance to side effect    | 4 (14.3%)              | 1 (3.6%)           |      |
| TACE course, number           | 2 (1–3)                |                    |      |
| Time to the first TACE, day   | 34 (11.3–63.0)         |                    |      |

Note—Data of continuous variables are presented as median values (interquartile range). AFP = alpha-fetoprotein, CLIP = the Cancer of the Liver Italian Program, Tx = treatment.

https://doi.org/10.1371/journal.pone.0188999.t001
months, 95% CI: 2.1–5.4 months; \( p < 0.01 \) (S1 Fig). After patient matching was performed, as shown in Fig 2, the 1-year survival rate in the TACE group remained significantly higher than that in the control group, after termination of sorafenib therapy (41.2%, 95% confidence interval [CI]: 19.4–63.0% vs. 24.5%, 95% CI: 6.3–42.7%; \( p < 0.01 \)). In addition, the median duration of patient survival in the TACE group was significantly longer than that of the control group (7.2 months, 95% CI: 5.4–15.7 months vs. 1.6 months, 95% CI: 0.1–4.0 months; \( p < 0.01 \)).

**Multivariate analysis of prognostic factors**

As shown in Table 2, in univariate analysis, we initially found several potential prognostic factors (\( p < 0.10 \)), including TACE treatment, AFP > 400ng/mL, Child-Pugh class, and tumor extension. After multivariate analysis, TACE treatment remained a significant factor, with a hazard ratio of 0.19 (95% CI: 0.08–0.42; \( p < 0.01 \)).

**Table 2. Multivariate analysis for overall survival.**

| Variable                          | Univariate analysis | Multivariate analysis |
|-----------------------------------|---------------------|-----------------------|
|                                   | HR                  | 95% CI                | \( p \) | HR     | 95% CI           | \( p \) |
| TACE treatment                    | 0.27                | 0.14–0.55             | < 0.01 | 0.19   | 0.08–0.42        | < 0.01 |
| Age > 60 years                    | 1.26                | 0.64–2.48             | 0.50   |        |                  |        |
| Male gender                       | 0.73                | 0.30–1.78             | 0.49   |        |                  |        |
| Child-Pugh class B                | 1.94                | 0.99–3.78             | 0.05   | 1.72   | 0.86–3.43        | 0.13   |
| Extrahepatic metastasis           | 1.59                | 0.78–3.24             | 0.20   |        |                  |        |
| Portal vein thrombosis            | 1.15                | 0.50–2.65             | 0.74   |        |                  |        |
| Tx-naïve before sorafenib therapy | 1.45                | 0.44–4.83             | 0.54   |        |                  |        |
| AFP > 400ng/mL                    | 1.80                | 0.92–3.52             | 0.08   | 1.41   | 0.71–2.81        | 0.33   |
| Tumor extension > 50%             | 1.87                | 0.91–3.84             | 0.09   | 2.99   | 1.31–6.82        | 0.01   |
| Stopping sorafenib due to side effect intolerance | 0.76 | 0.35–1.65 | 0.49 | |

Note—HR = Hazard ratio, CI = confidence interval, AFP = alpha-fetoprotein

https://doi.org/10.1371/journal.pone.0188999.t002
extension > 50% of the liver. After being adjusted by AFP > 400ng/mL, Child-Pugh class B, and tumor extension > 50% of the liver, TACE treatment was shown to be an independent prognostic factor associated with a decreased risk of mortality (HR: 0.19; 95% CI: 0.08–0.42; \( p < 0.01 \)). In contrast, tumor extension > 50% of the liver was considered to be an independent prognostic factor associated with an increased risk of mortality (HR: 2.99, 95% CI: 1.31–6.82; \( p < 0.01 \)). Other potential prognostic factors, such as age, gender, serum AFP levels, Child-Pugh class B, extrahepatic metastases, portal vein thrombosis, HCC treatment before sorafenib therapy, and stopping sorafenib therapy due to side effect intolerance, were not found to be significantly associated with patient mortality in this study.

Stratified analysis for TACE treatment

As shown in Fig 3, multivariate stratified analysis verified that TACE treatment was associated with a decreased mortality in each subgroup (all HR < 1.0). Furthermore, statistical significance was reached in most patient subgroups, including both age ≤ 60 and > 60 years, male gender, both AFP > 400ng/ml and ≤400 ng/ml, both Child-Pugh A and Child-Pugh B, with and without extrahepatic metastasis, with and without portal vein thrombosis, not treatment-naïve prior to sorafenib therapy, and tumor extension > 50% of the liver.

Adverse events of TACE

The laboratory parameters before and after the first TACE treatment have been listed in S3a Table, where the changes in laboratory parameters were shown to be insignificant. In addition, the rates of TACE-related adverse effects have been listed in S3b Table, where most adverse effects were transient in nature. In this study, although as many as 70% of patients had portal vein thrombosis, the rates of TACE-related adverse effects were not significantly different between the patient groups who did or didn’t experience portal vein thrombosis (S3c Table).

**Fig 3. Stratified analysis in patient subgroups.**

https://doi.org/10.1371/journal.pone.0188999.g003
Similar results could also be noted between the patient groups in Child-Pugh class A and B (S3d Table). Although only one (3.6%) patient with portal vein thrombosis (in Child-Pugh A) died of TACE-related liver failure, liver decompensation in patients (14.3%) remained an adverse effect that should be given much attention. However, analyzing for all causes of mortality showed that TACE did not increase the liver failure-related mortality rate when compared to those in the control group (S4 Table).

**Discussion**

Although TACE has been proven to be an effective treatment for locoregional HCC, the role of TACE treatment for advanced HCC after stopping sorafenib therapy remains unclear. To the best of our knowledge, this study was the first to reveal that TACE was shown to be an independent prognostic factor associated with decreased mortality risk after stopping sorafenib therapy. The findings of this study supported the theory that TACE treatment could be beneficial for select patients, however further prospective research remains mandatory for confirmation of our findings.

Upon failure of sorafenib therapy, the prognosis for patients with advanced HCC is generally poor, with a median survival period of only 4–8 months, as shown in previous studies [7,14]. These poor outcome results could be due to rapid tumor growth in the liver [7,8], with patient survival being possibly improved by means of controlling intrahepatic tumor growth. Although portal vein thrombosis has been traditionally considered a relative contraindication to TACE, recent studies have shown that TACE treatment could be safe due to the development of collateral circulation [4,13,25]. In patients experiencing portal vein thrombosis, TACE treatment may increase survival rates by 15–25% over a year [26–29], with a gain of 3–6 months over the median survival time [30]. In a recent meta-analysis of TACE for 1,933 HCC patients with main portal vein thrombosis, only 1% experienced liver failure, indicating that main portal vein thrombosis should not be considered as an absolute contraindication to TACE [31]. In this study, as many as 70% of patients experienced portal vein thrombosis, but the findings of this study still suggest that TACE could be beneficial in select patients with portal vein thrombosis.

According to the multivariable analysis in this study, tumor extension > 50% of the liver is another independent prognostic factor related to patient mortality, where a large tumor burden may reduce the tumor suppression effect of TACE. However, TACE was still beneficial for patients with large liver tumors in the subgroup analysis. Furthermore, in patients experiencing extrahepatic metastasis, as many as 80% of those patients may die of intrahepatic tumor progression [19,20]. Previous studies have suggested that TACE could be beneficial for survival in patients with extrahepatic metastasis, whilst controlling their intrahepatic tumors may thus still further improve patient survival [20,32]. As the findings in this study show, although approximately half of the patients had extrahepatic metastasis, TACE was still associated with a better patient survival rate during subgroup analysis.

Regorafenib is currently the only second-line treatment in phase 3 trials demonstrated to be survival-beneficial in patients with advanced HCC [14]. However, the median survival period in the regorafenib group was increased by only 2.8 months (10.6 months vs. 7.8 months), with a response rate of 11% in the regorafenib group. In addition, as many as 40% of patients in the regorafenib group could not tolerate the adverse effects and therefore discontinued regorafenib. Furthermore, regorafenib may not be affordable in most countries, whilst TACE remains a commonplace treatment worldwide. Although regorafenib may become standard therapy after the occurrence of sorafenib failure, other treatment choices should also be welcomed.
According to the findings in this study, TACE could be a treatment option after the stopping of sorafenib therapy for select patients.

Several limitations in this study should be mentioned. First, selection bias might exist in this retrospective study; e.g., clinicians may tend to suggest TACE treatment for patients who have a better life expectancy. However, in this study, important prognostic factors, such as Child-Pugh class and tumor burden, were well matched, while patients with severe liver decompensation (Child-Pugh class C), or poor performance status were excluded. Furthermore, in order to avoid any immortal time bias, the index date of outcome follow-up in the control group was matched with those in the TACE group. The selection bias should have been minimized. However, a well-controlled prospective study is important to confirm our findings. Second, the sample size of this study was relatively small, and the statistical analysis numbers for some patient subgroups might be undermanned. However, our study can still provide a clinically useful direction, while we realize that further studies with larger sample sizes should be encouraged. Third, although TACE was found to be effective in improving patient survival rates in this study, not all patients were suitable for TACE treatment after they stopped sorafenib therapy. Therefore, the rules for selecting patients for TACE should be further developed in the future.

In summary, TACE treatment after stopping sorafenib therapy for advanced HCC was found to be associated with a decreased mortality risk in this study. Therefore, TACE could be considered as a second-line treatment option.

Supporting information

S1 Fig. The 1-year survival rate in the two study groups before index date matching. (DOCX)

S1 Table. Baseline characteristics of the study subjects before patient matching. (DOCX)

S2 Table. Baseline characteristics of the study subjects before the initiation of sorafenib therapy. (DOCX)

S3 Table. The analysis on the adverse effects of TACE treatment (a) The laboratory parameters before and after the first TACE treatment; (b) The rates of TACE-related adverse effects; (c) The rates of TACE-related adverse effects in the patient groups with or without portal vein thrombosis. (DOCX)

S4 Table. All causes of mortality for the study subjects. (DOCX)

Acknowledgments

We thank the Biostatistics Task Force of Taichung Veterans General Hospital, Taichung, Taiwan, for statistical assistance. This study is based in part on data from the Taichung Veterans General Hospital Research Database and managed by Clinical Informatics Research & Development Center of Taichung Veterans General Hospital (Registered number F16391). The interpretation and conclusions contained herein do not represent those of Taichung Veterans General Hospital.
Author Contributions

**Conceptualization:** Yao-Kuang Huang, Sz-Iuan Shiu, Teng-Yu Lee.

**Data curation:** Yao-Kuang Huang, Chieh-Ling Yen, Sz-Iuan Shiu, Pi-Yi Chang, Teng-Yu Lee.

**Formal analysis:** Yao-Kuang Huang, Chieh-Ling Yen, Sz-Iuan Shiu, Shou-Wu Lee, Pi-Yi Chang, Teng-Yu Lee.

**Funding acquisition:** Teng-Yu Lee.

**Investigation:** Yao-Kuang Huang, Sz-Iuan Shiu, Shou-Wu Lee, Pi-Yi Chang, Teng-Yu Lee.

**Methodology:** Yao-Kuang Huang, Chieh-Ling Yen, Sz-Iuan Shiu, Pi-Yi Chang, Teng-Yu Lee.

**Project administration:** Hong-Zen Yeh, Teng-Yu Lee.

**Resources:** Hong-Zen Yeh, Teng-Yu Lee.

**Software:** Chieh-Ling Yen, Pi-Yi Chang, Teng-Yu Lee.

**Supervision:** Hong-Zen Yeh, Teng-Yu Lee.

**Validation:** Shou-Wu Lee, Hong-Zen Yeh, Teng-Yu Lee.

**Visualization:** Hong-Zen Yeh, Teng-Yu Lee.

**Writing – original draft:** Yao-Kuang Huang, Teng-Yu Lee.

**Writing – review & editing:** Shou-Wu Lee, Pi-Yi Chang, Hong-Zen Yeh, Teng-Yu Lee.

References

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012: CA Cancer J Clin 2015; 65(2):87–108. https://doi.org/10.3322/caac.21262 PMID: 25651787

2. Giannini EG, Farinati F, Ciccarese F, Pecorelli A, Rapaccini G L, Di Marco M, et al. Prognosis of untreated hepatocellular carcinoma. Hepatology 2015; 61:184–90. https://doi.org/10.1002/hep.27443 PMID: 25234419

3. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:359–75. https://doi.org/10.1056/NEJMoa0708857 PMID: 18650514

4. European Association For The Study Of The Liver, European Organisation For Research, Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56:908–43. https://doi.org/10.1016/j.jhep.2011.12.001 PMID: 22424438

5. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10:25–34. https://doi.org/10.1016/S1470-2045(08)70285-7 PMID: 19095497

6. Ogasawara S, Kanai F, Obi S, Sato S, Yamaguchi T, Azemoto R, et al. Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma. Hepatol Int. 2011 Sep; 5(3):850–6. https://doi.org/10.1007/s12072-010-9249-4 PMID: 21484134

7. Lee IC, Chen YT, Chao Y, Huo TI, Li OP, Su CW, et al. Determinants of survival after sorafenib failure in patients with BCLC-C hepatocellular carcinoma in real-world practice. Medicine 2015; 94:e688. https://doi.org/10.1097/MD.0000000000000668 PMID: 25860213

8. Reig M, Rimola J, Torres F, Darnell A, Rodriguez-Lope C, Forner A, et al. Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design. Hepatology 2013; 58:2023–38. https://doi.org/10.1002/hep.26586 PMID: 23787822

9. Lee JE, Bae SH, Choi JY, Yoon SK, Yoo YK, Lee MA. Epirubicin, cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma. World J Gastroenterol 2014; 20:235–41. https://doi.org/10.3748/wjg.v20.i1.235 PMID: 24415877

10. Zhu AX, Kudo M, Assenat E, Cattan S, Kang YK, Lim HY, et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. JAMA 2014; 312:57–67. https://doi.org/10.1001/jama.2014.7189 PMID: 25058218
11. Yau T, Wong H, Chan P, Yao TJ, Pang R, Cheung TT, et al. Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease. Invest New Drugs 2012; 30:2384–90. https://doi.org/10.1007/s10637-012-9808-8 PMID: 22402942

12. Llovet JM, Decaens T, Raoul JL, Boucher E, Kudo M, Chang C, et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol 2013; 31:3509–16. https://doi.org/10.1200/JCO.2012.47.3009 PMID: 23980090

13. Bruix J, Sherman M, American Association for the Study of Liver Disease. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53:1020–2. https://doi.org/10.1002/hep.24199 PMID: 21374666

14. Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017 Jan; 389(10064):56–66. https://doi.org/10.1016/S0140-6736(16)32453-9 PMID: 27932229

15. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002 May; 359:1734–9. https://doi.org/10.1016/S0140-6736(02)08649-X PMID: 12049862

16. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003; 37:429–42. https://doi.org/10.1053/jhep.2003.50047 PMID: 12540794

17. Zhao Y, Cai G, Zhou L, Liu L, Qi X, Bai M, et al. Transarterial chemoembolization in hepatocellular carcinoma with vascular invasion or extrahepatic metastasis: A systematic review. Asia Pac J Clin Oncol 2013; 9:357–64. https://doi.org/10.1111/acoj.12081 PMID: 23714021

18. Zhao Y, Duran R, Chapario J, Sohn JH, Sahu S, Fleckenstein F, et al. Transarterial Chemoembolization for the Treatment of Advanced-Stage Hepatocellular Carcinoma. J Gastrointest Surg 2016; 20:2002–9. https://doi.org/10.1007/s11605-016-3285-x PMID: 27714643

19. Yoo DJ, Kim KM, Jin YJ, Shim JH, Ko GY, Yoon HK, et al. Clinical outcome of 251 patients with extrahepatic metastasis at initial diagnosis of hepatocellular carcinoma: does transarterial chemoembolization improve survival in these patients? J Gastroenterol Hepatol 2011; 26:145–54. https://doi.org/10.1111/j.1440-1746.2010.06341.x PMID: 21175808

20. Uka K, Akata H, Takaki S, Shirakawa H, Jeong SC, Yamashina K, et al. Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma. World J Gastroenterol 2007; 13:414–20. https://doi.org/10.3748/wjg.v13.i3.414 PMID: 17230611

21. Tan CH, Low SC, Thng CH, APASL and AASLD Consensus Guidelines on Imaging Diagnosis of Hepatocellular Carcinoma: A Review. Int J Hepatol 2011; 2011:519783. https://doi.org/10.4061/2011/519783 PMID: 22007313

22. Surveillance group; Diagnosis group; Staging group; Surgery group; Local ablation group; TACE/TARE/HAI group, et al. Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. J Formos Med Assoc. 2017 (forthcoming).

23. Shariff SZ, Cuerden MS, Jain AK, Garg AX. The secret of immortal time bias in epidemiologic studies. J Am Soc Nephrol 2008; 19:841–843 https://doi.org/10.1681/ASN.2007121354 PMID: 18322159

24. Lee TY, Lin JT, Zeng YS, Chen YJ, Wu MS, Wu CY et al. Association between nucleos(t)ide analog and tumor recurrence in hepatitis B virus-related hepatocellular carcinoma after radiofrequency ablation. Hepatology 63(5): 1517–1527 https://doi.org/10.1002/hep.28266 PMID: 26426978

25. Jelic S, Sotiropoulos GC, Group EGW. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 Suppl 5:v59–64.

26. Georgiades CS, Hong K, D’Angelo M, Geschwind JF. Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 2005; 16:1653–9. https://doi.org/10.1097/01.RVI.0000182185.47500.7A PMID: 16371532

27. Luo J, Guo RP, Lai EC, Zhang YJ, Lau WY, Chen MS, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. Ann Surg Oncol 2011; 18:413–20. https://doi.org/10.1245/s10434-010-1321-8 PMID: 20839057

28. Leng JJ, Xu YZ, Dong JH. Efficacy of transarterial chemoembolization for hepatocellular carcinoma with portal vein thrombosis: a meta-analysis. ANZ J Surg 2016; 86:816–20. https://doi.org/10.1111/ans.12803 PMID: 25088384

29. Xue TC, Xie XY, Zhang L, Yin X, Zhang BH, Ren ZG. Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a meta-analysis. BMC Gastroenterol 2013; 13:60. https://doi.org/10.1186/1471-230X-13-60 PMID: 23566041
30. Niu ZJ, Ma YL, Kang P, Ou SQ, Meng ZB, Li ZK, et al. Transarterial chemoembolization compared with conservative treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus: using a new classification. Med Oncol 2012; 29:2992–7 https://doi.org/10.1007/s12032-011-0145-0 PMID: 22200992

31. Silva JP, Berger NG, Tsai S, Christians KK, Clarke CN, Mogal H, et al. Transarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis. HPB (Oxford). 2017 Aug; 19(8):659–666

32. Yoo JJ, Lee JH, Lee SH, Le M, Lee DH, Cho Y, et al. Comparison of the effects of transarterial chemoembolization for advanced hepatocellular carcinoma between patients with and without extrahepatic metastases. PloS one 2014; 9:e113926. https://doi.org/10.1371/journal.pone.0113926 PMID: 25427152